L'Oréal and Micreos, which develops new biological therapies based on phage and endolysin technology, have signed a license agreement to join their expertise in biotechnology and the skin microbiome. Under the terms of the agreement, Micreos will give L'Oréal access to its endolysin, a type of active protein in the cosmetic field. With this technology, it is possible for the first time to target only unwanted bacteria in the skin flora, according to Micreos.   For 15 years, L&#039...